Good news in treatment of esophageal cancer

Dr. Ilson's editorial in the New England Journal of Medicine puts new findings regarding the monoclonal antibody, nivolumab, in treatment of esophagal cancer in perspective. [Figure from original research article by Kelly, et al in same issue]

N Engl J Med. 2021 Apr 1;384(13):1269-1271.
doi: 10.1056/NEJMe2101983.

Adjuvant Nivolumab in Esophageal Cancer - A New Standard of Care
David H Ilson

PMID: 33789017 DOI: 10.1056/NEJMe2101983

Excerpt from conclusion:

CheckMate 577 is a practice-changing trial in the treatment of  esophageal cancer. Although overall survival data are not mature, the  doubling of median disease-free survival will almost certainly translate  into an overall survival benefit. The trial shows the first true  advance in the adjuvant therapy of esophageal cancer in recent years and  will become a new standard of care. However, despite the improvement  observed, most patients will not gain benefit from adjuvant therapy with  nivolumab. More contemporary biomarkers, including the presence of  persistent circulating tumor DNA after surgery, should be explored to  better define high-risk populations and potentially monitor patients  receiving adjuvant therapy.
About
This website contains a curated and opinionated look at recent literature regarding the epidemiology and prevention of esophageal cancer, with an emphasis on esophageal adenocarcinoma. It is developed by Thomas L Vaughan MD, MPH, who can be reached with questions or suggestions through email or his research website.
©2021 Thomas L Vaughan
Disclaimer
This website should not be considered, or used as a substitute for, medical advice, diagnosis or treatment. This site does not constitute the practice of any medical or other professional health care advice, diagnosis or treatment. The information on this website represent the views solely of Dr. Vaughan.
Privacy
Cookies are used to quantify website use for resource planning.  Complete IP addresses are not collected (i.e.,  203.0.113.123 will be  recorded as 203.0.113.??) Feel free to opt out of cookies using add-ins of your choice without affecting website function.  No user information is collected by the risk calculator (IC-RISC).